Omaha, NE Streck, Inc., introduces LBC?Chex, the first and only lamellar body count control on the
market. Lamellar bodies have been analyzed as an indirect estimate of fetal lung maturity and potential
indicator of respiratory distress syndrome.
LBC?Chex is convenient and easy to use. Technicians use the control in the same manner as a patient
sample of amniotic fluid no dilution required, which saves time and reduces the potential for testing
LBC?Chex verifies the hematology instrument is accurate for the lower linearity limit of the platelet (PLT)
parameter. Available in three clinically significant levels, LBC?Chex tests lower parameters than standard
CBC controls and calibration materials. It is assayed for the Sysmex® XE?2100 and XE?5000, and
Beckman Coulter® LH 700 series and UniCel® DxH 800.
LBC?Chex features 30?day open?vial stability and 105?day closed?vial stability. It is packaged in plastic
3.0ml cap?pierceable vials.
For Research Use Only. Not for use in diagnostic procedures
Streck also offers Cell?Chex®, a body fluid procedural control for red blood cell and white blood cell
counts, crystal identification and white blood cell differentiation; and Cell?Chex® Auto, a three?level
spinal and body fluid control for evaluating the accuracy and precision of hematology instruments that
measure blood cell counts in patient body fluid samples.
About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The companys pursuit of innovative solutions has produced an extensive list of patented products. Strecks core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit www.streck.com.